Use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role

摘要

The present invention relates to the use of inhibitors of the expressed proteins of TCF target genes whose expression is regulated by TCF/beta-catenin complexes for the preparation of a therapeutical composition for the treatment of cancers in which TCF/beta-catenin signaling is deregulated. Such inhibitors can be antibodies, small molecules, antisense RNA and dsRNA for use in RNAi. The invention also relates to these inhibitors per se.